Lizonab Tablet contains Linezolid 600 mg, an oxazolidinone-class antibiotic effective against a broad spectrum of Gram-positive bacterial infections. It is primarily indicated for the treatment of serious infections caused by susceptible strains of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and penicillin-resistant Streptococcus pneumoniae. Lizonab is commonly prescribed for conditions such as complicated skin and soft tissue infections, nosocomial and community-acquired pneumonia, and infections caused by multidrug-resistant organisms. Linezolid exerts its antibacterial effect by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex essential for bacterial translation. The oral formulation of Lizonab offers excellent bioavailability, allowing for effective systemic therapy. It is generally well-tolerated, although potential adverse effects include myelosuppression, peripheral and optic neuropathy, and serotonin syndrome, particularly when used concomitantly with serotonergic agents. Monitoring of blood counts is recommended during prolonged therapy. Lizonab should be used under strict medical supervision, adhering to prescribed dosages to minimize resistance development and ensure optimal therapeutic outcomes.